ArticleEBioMedicine2026
Higher amyloid deposition and lower white matter volume in cognitively healthy seniors exceeding French alcohol recommendations.
Article in EBioMedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundOlder adults are particularly vulnerable to alcohol's effects. Our aim was to establish whether differences in neurocognitive health exist between cognitively healthy seniors, depending on whether they follow recent French health recommendations for stricter drinking limits beyond age 65.
methodsWe conducted a retrospective cross-sectional study including 133 community-dwelling cognitively healthy participants aged over 65 from the Age-Well Study. Based on their compliance with recommendations, participants were classified as lower-risk or higher-risk. Neurocognitive health was assessed comprehensively through standard cognitive testing, and voxel-wise analyses of structural integrity and cortical amyloid PET burden.
findingsHigher-risk participants displayed more neocortical amyloid deposition (F = 7.577; p = 0.007; d = 0.553) and lower cerebral volume, in the absence of a difference in cognition (p > 0.1).
interpretationThese results highlight that alcohol consumption exceeding age-specific recommendations is associated with lower brain integrity, notably including elevated amyloid burden, a biomarker strongly linked with higher risk of Alzheimer's disease-related cognitive decline and dementia. Our findings emphasise the importance of strict adherence to lower-risk thresholds in older populations.
fundingEuropean Union's Horizon 2020 Research and Innovation Programme (No 667696); Institut National de la Santé et de la Recherche Médicale (INSERM); Fondation Entrepreneurs MMA; FONDATION ALZHEIMER; Région Normandie; Fondation Recherche Alzheimer; Association France Alzheimer; Fondation de France; Institut pour la Recherche en Santé Publique (IRESP).
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.